Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This study makes an observation over the objective response rate of Apatinib and XELOX
combination regimen in the first-line treatment of metastatic colorectal cancer. All the
participants will receive the treatment of Apatinib and XELOX combination regimen.